In rheumatoid arthritis, existing therapies frequently fall short of delivering sustained disease control, despite sequential use of biologic and targeted agents. In a this episode of the ๐๐ฎ๐๐ฒ ๐๐ผ ๐๐ฎ๐๐ฒ ๐๐ถ๐ผ๐๐ฒ๐ฐ๐ต ๐ฃ๐ผ๐ฑ๐ฐ๐ฎ๐๐, Lisa Guerrettaz, Executive Director, Pharmacology and Translational Science at Artiva Biotherapeutics, discusses how the limitations of currently approved treatments are driving the development…
